New Zealand markets closed

Spyre Therapeutics, Inc. (SYRE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
36.49+2.82 (+8.38%)
At close: 04:00PM EDT
36.49 0.00 (0.00%)
After hours: 05:05PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.85B
Enterprise value 1.70B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)799.51
Price/book (mrq)N/A
Enterprise value/revenue 2.47k
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 2.96
52-week change 3957.68%
S&P500 52-week change 322.70%
52-week high 347.97
52-week low 32.65
50-day moving average 335.37
200-day moving average 323.73

Share statistics

Avg vol (3-month) 3380.36k
Avg vol (10-day) 3334.99k
Shares outstanding 550.78M
Implied shares outstanding 650.78M
Float 833.09M
% held by insiders 13.93%
% held by institutions 169.47%
Shares short (15 May 2024) 44.52M
Short ratio (15 May 2024) 414.3
Short % of float (15 May 2024) 414.35%
Short % of shares outstanding (15 May 2024) 411.21%
Shares short (prior month 15 Apr 2024) 43.56M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:25
Last split date 308 Sept 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-21,305.23%

Management effectiveness

Return on assets (ttm)-33.93%
Return on equity (ttm)-391.81%

Income statement

Revenue (ttm)688k
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -146.03M
Net income avi to common (ttm)-364.22M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)484.64M
Total cash per share (mrq)12.03
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)11.38
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-110.82M
Levered free cash flow (ttm)-4.34M